Close
Smartlab Europe
Achema middle east

News

WuXi STA to build new R&D center in Shanghai

STA Pharmaceutical Co., Ltd., a subsidiary of WuXi AppTec (WuXi STA), announces that it has signed an investment agreement with the government of Shanghai, Jinshan District to build a new R&D center. The new facility will...

Vetter welcomes Illinois Governor Bruce Rauner to its German Facilities

Vetter, a global leader in prefilled drug-delivery systems was paid a special visits at its Ravensburg, Germany facilities by Illinois Governor, Bruce Rauner. The governor was accompanied by a delegation of approximately twenty key state and...

CRF Health’s TrialMax eCOA Solution Selected for Landmark Pain Outcomes Study by Global Japanese Pharmaceutical Company

CRF Health, the leading provider of patient-centered eSource for the life sciences industry, announced that its TrialMax Touch® and TrialMax Slate® solutions have been selected by a Global Category Japanese Pharmaceutical company for a significant pain trial. ...

Discover Strategies to Maintain a Global Pharmacovigilance System this June at SMi’s 5th Drug Safety conference

Drug Safety 2018 aims to discuss the latest findings and current thinking on pharmacovigilance. Importantly, it will address the newest regulatory updates and interpretations of them, including the impact of the vital and much awaited Clinical Trial Regulations. ...

SMi’s HPAPI 2018 Conference: Exclusive Interview Released with HPAPI Project Services

SMi are delighted to have our Chairman, Speaker and Workshop Host, Justin Mason-Home, Director, HPAPI Project Services Limited, onto the speaker panel for HPAPI 2018! About Justin:Justin Mason-Home is an organic chemist with extensive health, safety,...

1st-line Tagrisso demonstrates sustained benefit post progression in patients with EGFR-mutated non-small cell lung cancer

AstraZeneca presented new post-progression outcomes data from an exploratory analysis of the global Phase III FLAURA trial, which assessed the efficacy and safety of Tagrisso (osimertinib) as 1st-line therapy in patients with locally advanced or metastatic epidermal growth factor...

Novartis announces new analysis demonstrating Entresto helped preserve kidney function in patients with chronic heart failure, especially those with diabetes

Novartis announced a new post hoc analysis of the pivotal Phase III heart failure study, PARADIGM-HF, demonstrating that treatment with Entresto® (sacubitril/valsartan) helped to preserve kidney function, as assessed by estimated glomerular filtration rate (eGFR), in patients with heart...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »